

Claim 1 (Currently Amended). A method for treating fungal infections in a mammal, comprising:

providing a composition that comprises an active ingredient that includes Amphotericin B, wherein the Amphotericin B compound is present in an amount greater than ~~about 92~~ 96% with no greater than ~~about 8~~ 4% of impurity products, and a pharmaceutically effective carrier; and

administering a therapeutically effective amount of said composition to a subject in need thereof.

Claim 2 (Canceled).

Claim 3 (Previously Presented). The method of claim 1, wherein the amphotericin B is present in an amount greater than about 98% and no greater than about 2% of impurity products.

Claim 4 (Original). The method of claim 1, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 5 (Original). The method of claim 1, wherein the administering step is intravenous.

Claim 6 (Currently Amended). A pharmaceutical composition, comprising:

an active ingredient that has at least ~~92~~ 96% of an amphotericin B compound and no greater than ~~8~~ 4% of impurity products, and a pharmaceutically acceptable carrier.

Claim 7 (Canceled).

Claim 8 (Previously Presented). The composition of claim 6, wherein the amphotericin B compound is present in an amount greater than about 98%.


Claims 9-16 (canceled).

Claim 17 (Previously Presented). The method of claim 1, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 18 (Previously Presented). The composition of claim 6, wherein the impurities comprise at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 19 (Previously Presented). A pharmaceutical composition that comprises:

an active ingredient that is at least 96% w/w of a compound of the following formula:



and a pharmaceutically acceptable carrier.


Claim 20 (Previously Presented). The composition of claim 19, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 21 (Previously Presented). The composition of claim 19, the active ingredient comprising no greater than 4% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound.

Claim 22 (Currently Amended). A method for treating fungal infections in a mammal, comprising:

providing a composition that comprises an active ingredient that has at least 92 96% amphotericin B polyene compound and a pharmaceutically effective carrier; and administering a therapeutically effective amount of said composition to a subject in need thereof.

Claim 23 (Previously Presented). The method of claim 22, wherein the active ingredient that is at least 96% w/w of a compound of the following formula:



and a pharmaceutically acceptable carrier.


Claim 24 (Previously Presented). The method of claim 22, wherein said pharmaceutically acceptable carrier is a lipid carrier.

Claim 25 (Canceled).

Claim 26 (Canceled).

Claim 27 (Currently Amended). A pharmaceutical composition that comprises:

an active ingredient that is at least 92 96% w/w of a compound of the following formula:




comprising no greater than 8 4% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound,

and a pharmaceutically acceptable carrier.

Claim 28 (New). The composition of claim 27, wherein said pharmaceutically acceptable carrier is a lipid carrier.


Claim 29 (Currently Amended). The composition of claim 27, wherein

(a) the active ingredient is at least 94% w/w of a compound of the following formula:




and comprises no greater than 6% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound; or

(b) the active ingredient is at least 96% w/w of a compound of the following formula:



and comprises no greater than 4% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound; or

(e) the active ingredient is at least 98% w/w of a compound of the following formula:



and comprises no greater than 2% w/w of at least one of a non-amphotericin B polyene compound or an endotoxin compound; and

and a pharmaceutically acceptable carrier.

Claim 30 (Canceled).